Condition: Systemic Lupus Erythematosus (SLE) · Immune-mediated Necrotizing Myopathy (IMNM) · Neuromyelitis Optica Spectrum Disorders (NMOSD) · Sponsor: RenJi Hospital
This is an investigator-initiated, multicenter, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
This description comes directly from the study's public registry record.
Nan Shen, MD & PhD · +86-21-63260477 · nanshensibs@gmail.com
Huihua Ding, MD · +86-21-53882280 · dinghuihua@outlook.com
Always discuss trial participation with your own doctor first.
| Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06249438